Marginal zone B-cell lymphoma or Marginal Zone Lymphoma (MZL) is a group of indolent (slow-growing) NHL B-cell lymphomas, which account for approximately 5‒17% of all NHL cases. MZLs consist of three different subtypes with extranodal being the most commonly reported, representing 50‒70% of MZL, followed by splenic (20%) and nodal (10%).
Currently, the first-line management of MZL totally depends on supportive therapies, and the two therapies that are approved are for relapsed and refractory MZL patient pool. Additionally, all the emerging therapies that are expected to launch in the forecasted period are also focusing on the relapsed and refractory MZL pool. The market is expected to grow by factors like an increase in the patient pool, expected entry of emerging therapies, i.e., such as Ublituximab, Duvelisib, Umbralisib (TGR-1202), and deeper penetration in the 7MM markets.
Get FREE sample copy at:
The Marginal Zone Lymphoma market report also covers emerging drugs, current treatment practices, Marginal Zone Lymphoma market share of the individual therapies, current and forecasted Marginal Zone Lymphoma Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Marginal Zone Lymphoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Marginal Zone Lymphoma Market Key Facts
The total incident population of Non-Hodgkin lymphoma (NHL) in the 7MM was estimated to be 166,967 in 2017. Out of these the total incident population of Marginal Zone Lymphoma in the 7MM in 2017 was observed to be 21,284.
Based on the stages of the disease, Marginal Zone Lymphoma is divided into three stages. The epidemiological model of DelveInsight estimates a higher proportion of MZL cases was found in stage III as compared to other stages in the United States. In 2017, stage I, stage II, and stage III MZL incident cases were 1,416, 465 and 5,307 respectively, in the US.
Among the EU5 countries, the UK had the highest incident population of Marginal Zone Lymphoma with 3,142 cases, followed by France which had an incident population of 1,748 in 2017.
The United States showed the highest incident cases of Marginal Zone Lymphoma, as compared to EU5, and Japan. As per the estimates, the US accounts for approximately 33.9% of total cases, for MZL, in the 7MM countries.
Key Benefits of Marginal Zone Lymphoma Market Report
Marginal Zone Lymphoma market report provides an in-depth analysis of Marginal Zone Lymphoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The Marginal Zone Lymphoma market report will help in developing business strategies by understanding the Marginal Zone Lymphoma Market trends & developments, key players, and future market competition that will shape and drive the Marginal Zone Lymphoma market in the upcoming years.
The Marginal Zone Lymphoma market report covers Marginal Zone Lymphoma current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Marginal Zone Lymphoma market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Marginal Zone Lymphoma market size in the 7MM was found to be USD 427.16 Million in 2017. Marginal Zone Lymphoma market size is expected to increase during the forecast period owing to the increasing incident population of MZL patients in the 7MM and the launch of upcoming therapies during the forecast period.
The Marginal Zone Lymphoma market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Marginal Zone Lymphoma market trends by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Marginal Zone Lymphoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Marginal Zone Lymphoma Epidemiology
In 2017, a higher number of males were affected by this disease, i.e., 54% of the total incident Marginal Zone Lymphoma population in the United States, which is equivalent to 3,882 cases. In comparison to this, for females, the number of cases observed was 3,307 in 2017.
The Marginal Zone Lymphoma epidemiology section covers insights about the historical and current Marginal Zone Lymphoma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Marginal Zone Lymphoma Drugs Uptake and Key Market Players
The Marginal Zone Lymphoma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Marginal Zone Lymphoma market or expected to get launched in the market during the study period. The analysis covers Marginal Zone Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Treatment selection for a patient with Marginal Zone Lymphoma (MZL) depends on the type, stage, and location of the disease. According to the Lymphoma Organization, Marginal Zone Lymphoma is also divided into three different subtypes MALT/extranodal, nodal MZL, and splenic MZL. The total Market of Marginal Zone Lymphoma is categorized into three types based on the line of therapies, i.e., first-line, second-line, and third-line of therapies.
Several pharmaceutical key players have taken the initiative to meet the unmet needs of the present situation of the Marginal Zone Lymphoma market. Some of the key players are in the late and mid clinical development stages with their leading drug candidates. The launch of emerging products during the forecast period will fuel the Marginal Zone Lymphoma market growth.
Marginal Zone Lymphoma Companies:
TriSalus Life Sciences
And many others
Marginal Zone Lymphoma Therapies covered in the report include:
Revlimid (lenalidomide) in combination with rituximab
Yescarta (axicabtagene ciloleucel)
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Marginal Zone Lymphoma Competitive Intelligence Analysis
4. Marginal Zone Lymphoma Market Overview at a Glance
5. Marginal Zone Lymphoma Disease Background and Overview
6. Marginal Zone Lymphoma Patient Journey
7. Marginal Zone Lymphoma Epidemiology and Patient Population
8. Marginal Zone Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Marginal Zone Lymphoma Unmet Needs
10. Key Endpoints of Marginal Zone Lymphoma Treatment
11. Marginal Zone Lymphoma Marketed Products
12. Marginal Zone Lymphoma Emerging Therapies
13. Marginal Zone Lymphoma Seven Major Market Analysis
14. Attribute Analysis
15. Marginal Zone Lymphoma Market Outlook (7 major markets)
16. Marginal Zone Lymphoma Access and Reimbursement Overview
17. KOL Views on the Marginal Zone Lymphoma Market.
18. Marginal Zone Lymphoma Market Drivers
19. Marginal Zone Lymphoma Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Related Reports By DelveInsight
Marginal Zone Lymphoma Epidemiology Forecast
DelveInsight’s Marginal Zone Lymphoma – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of the Marginal Zone Lymphoma in the 7MM.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States